{
    "clinical_study": {
        "@rank": "137994", 
        "arm_group": [
            {
                "arm_group_label": "23-valent Pneumococcal Polysaccharide vaccine", 
                "arm_group_type": "Active Comparator", 
                "description": "0.5ml 23-valent pneumococcal Polysaccharide vaccine made by Chengdu Institute of Biological Products Co.,Ltd.\nlot number: 20130106-1, duration:JAN,17,2015."
            }, 
            {
                "arm_group_label": "Trivalent Influenza Vaccine", 
                "arm_group_type": "Active Comparator", 
                "description": "0.5ml trivalent influenza vaccine made by Shanghai Institute of Biological Products Co.,Ltd.\nlot number:20130713, duration:Jul,1,2014."
            }, 
            {
                "arm_group_label": "23vPPV+TIV", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The 23-valent pneumococcal Polysaccharide vaccine (23vPPV) has been developed for children\n      and adults to prevent pneumococcal diseases such as pneumonia (inflammation of the lungs),\n      meningitis (inflammation of the brain lining), and septicemia (blood poisoning) since 2006\n      in China. Also, the trivalent influenza vaccine (TIV) is frequently administered to the\n      children and adults. The main objective of this study is to show that both vaccines can\n      safely be administered together without affecting the immune response of protecting against\n      disease."
        }, 
        "brief_title": "Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Pneumococcal Infection", 
            "Influenza"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Influenza, Human", 
                "Pneumococcal Infections"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Generally healthy male or female, for adults 50-65 years of age, for children 3-7\n             years of age.\n\n          2. Available for the duration of the trial - approximately 2 months.\n\n          3. No history of severe adverse reaction associated with a vaccine.\n\n        Exclusion Criteria:\n\n          1. Subject that has a medical history of any of the following: allergic history, or\n             allergic to any ingredient of vaccine, such as egg, egg protein, etc.\n\n          2. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory\n             difficulty, angioedema, or abdominal pain.\n\n          3. Autoimmune disease or immunodeficiency.\n\n          4. Asthma that is unstable or required emergent care, hospitalization or intubation\n             during the past two years or that required the use of oral or intravenous\n             corticosteroids.\n\n          5. Diabetes mellitus (type I or II), with the exception of gestational diabetes History\n             of thyroidectomy or thyroid disease that required medication within the past 12\n             months.\n\n          6. Serious angioedema episodes within the previous 3 years or requiring medication in\n             the previous two years.\n\n          7. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or\n             platelet disorder requiring special precautions) or significant bruising or bleeding\n             difficulties with IM injections or blood draws.\n\n          8. Any history of immunosuppressive medications or cytotoxic medications or inhaled\n             corticosteroids within the past six months (with the exception of corticosteroid\n             nasal spray for allergic rhinitis or topical corticosteroids for an acute\n             uncomplicated dermatitis)\n\n          9. History of any blood products or seasonal influenza vaccine administration within 3\n             months before the dosing.\n\n         10. Administration of any other investigational research agents within 30 days before the\n             dosing.\n\n         11. Administration of any live attenuated vaccine within 30 days before the dosing\n             Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or\n             allergy treatment with antigen injections, within 14 days before the dosing.\n\n         12. Axillary temperature > 37.0 centigrade at the time of dosing.\n\n         13. Psychiatric condition that precludes compliance with the protocol.\n\n         14. Any medical, psychiatric, social condition, occupational reason or other\n             responsibility that, in the judgment of the investigator, is a contraindication to\n             protocol participation or impairs a volunteer's ability to give informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "2225", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02062281", 
            "org_study_id": "JSEPI-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "23-valent Pneumococcal Polysaccharide vaccine", 
                "description": "Single 0.5ml 23-valent pneumococcal polysaccharide vaccine was administered intramuscularly (IM)", 
                "intervention_name": "23-valent pneumococcal polysaccharide vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Trivalent Influenza Vaccine", 
                "description": "Single 0.5ml trivalent influenza vaccine  was administered IM", 
                "intervention_name": "trivalent influenza vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "23vPPV+TIV", 
                "description": "Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.", 
                "intervention_name": "23vPPV+TIV", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Safety", 
            "Immunogenicity", 
            "vaccine", 
            "pneumococcal", 
            "influenza"
        ], 
        "lastchanged_date": "February 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zhenjiang", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "212200"
                }, 
                "name": "Yangzhong Center for Disease Control and Prevention"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 4, Randomized, Single-blind Trial to Evaluate Safety and Immunogenicity of a 23-Valent Pneumococcal Polysaccharide Vaccine When Administered Simultaneously With Trivalent Inactivated Influenza Vaccine in Healthy Children Aged 3-7years and Healthy Adults 65 Aged 50-65years.", 
        "overall_official": {
            "affiliation": "jiangsu CDC", 
            "last_name": "ma fubao, doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "IgG GMC measured by enzyme-linked immunosorbent assay (ELISA) and expressed in micrograms per mL (mcg/mL) for serotypes 1,2,5,6B,14,19F,23F,which were frequently detected in patients in Chinese.", 
                "measure": "Immunogenicity of 23vPPV", 
                "safety_issue": "No", 
                "time_frame": "1 month after 23vPPV vaccination"
            }, 
            {
                "description": "Percentage of participants achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI)", 
                "measure": "Immunogenicity of TIV", 
                "safety_issue": "No", 
                "time_frame": "1 month after TIV vaccination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02062281"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "adverse events following the immunization (AEFI)", 
            "safety_issue": "Yes", 
            "time_frame": "28 days after 23vPPV  and TIV vaccination"
        }, 
        "source": "Jiangsu Province Centers for Disease Control and Prevention", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Chengdu Institute of Biological Products Co.,Ltd.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Shanghai Institute Of Biological Products", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Jiangsu Province Centers for Disease Control and Prevention", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}